Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Halcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.71 |
| ▸ | PGR | P06401 | 5/20 | 0.71 |
| ▸ | AR | P10275 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.66 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halcinonide SCHEMBL2637394 | 0.87 | CYP3A4 (0.73) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL28142872 | 0.87 | CYP3A4 (0.76) | CYP3A4NR3C1PGRARUSP2 | |
| Fluocinolone Acetonide SCHEMBL22807167 | 0.84 | NR3C1 (0.73) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL5188866 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL4336 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL24015431 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL8467031 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL7861670 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL4335 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 | |
| Halcinonide SCHEMBL5489567 | 0.84 | NR3C1 (1.00) | CYP3A4NR3C1PGRARUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431601-B2 | Topical compositions comprising telmesteine for treating dermatological disorders | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2013-04-30 | — | — | US | disclosed |
| US-20120142605-A1 | METHODS OF TREATING PSORIASIS | AMGEN INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110280869-A1 | METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS | MEDIMMUNE, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| EP-1670464-B1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | SINCLAIR PHARMACEUTICALS LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010129707-A1 | ETANERCEPT IN COMBINATION WITH GLUCOCORTICOIDS FOR USE IN TREATING PSORIASIS | AMGEN INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100130568-A1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2010-05-27 | — | — | US | disclosed |
| US-20090186021-A1 | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents | MEDLMMUNE, INC | 2009-07-23 | — | — | US | disclosed |
| US-20080114057-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE MUCOSAE, SKIN AND THE EYE | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080015155-A1 | Compositions and Methods for the Treatment of Inflammatory Conditions of the Mucosae, Skin and the Eye | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2008-01-17 | — | — | US | disclosed |
| US-20070213381-A1 | Topical Compositions Comprising Telmesteine for Treating Dermatological Disorders | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2007-09-13 | — | — | US | disclosed |
| CN-1863529-A | Topical compositions comprising telmesteine for treating skin conditions | SINCLAIR PHARMACEUTICALS LTD (GB) | 2006-11-15 | — | — | CN | disclosed |
| US-20060247183-A1 | Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2006-11-02 | — | — | US | disclosed |
| US-20060178351-A1 | Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents | NOVACEA, INC. | 2006-08-10 | — | — | US | disclosed |
| EP-1670464-A1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | Sinclair Pharmaceuticals Limited (GB) | 2006-06-21 | — | — | EP | disclosed |
| EP-1631297-A2 | TREATMENT OF IMMUNE-MEDIATED DISORDERS WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS | Novacea, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050143324-A1 | Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye | SINCLAIR PHARMACEUTICALS, LTD. | 2005-06-30 | — | — | US | disclosed |
| WO-2005037275-A1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004110380-A2 | TREATMENT OF IMMUNE-MEDIATED DISORDERS WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS | NOVACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20030044406-A1 | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents | MEDIMMUNE, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002069904-A2 | CD2 ANTAGONISTS FOR TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASE | MEDIMMUNE, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178351-A1 | Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents | VDR, CYP24A1, CYP2R1 | NR3C1 368/4885CYP3A4 2124/4885PGR 3308/4885 |
| US-20070213381-A1 | Topical Compositions Comprising Telmesteine for Treating Dermatological Disorders | TSLP, TYR, ITCH | NR3C1 1908/4885CYP3A4 4051/4885PGR 2892/4885 |
| US-20100130568-A1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | TSLP, TYR, ITCH | NR3C1 1908/4885CYP3A4 4051/4885PGR 2892/4885 |
| US-20120142605-A1 | METHODS OF TREATING PSORIASIS | TNF, TSLP, IL17A | NR3C1 6/4885CYP3A4 2735/4885PGR 456/4885 |
| US-20110280869-A1 | METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS | CD2, CD22, CD2BP2 | NR3C1 1050/4885CYP3A4 3568/4885PGR 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.